Physician profile
Steven A Chomsky
NPI 1619016920
$1,551.34
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $75.73 · 2021: $72.18 · 2022: $29.46.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $569.82 | 2019 | |
| Viiv Healthcare Company | $165.37 | 2019-2022 | |
| Medtronic Vascular, INC. | $133.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $124.83 | 2019 | |
| Glaxosmithkline, LLC. | $118.24 | 2019 | |
| Lilly USA, LLC | $111.82 | 2019 | |
| Neurocrine Biosciences, INC. | $76.26 | 2019 | |
| Merck Sharp & Dohme LLC | $68.86 | 2019-2020 | |
| Janssen Biotech, INC. | $51.94 | 2019 | |
| Abbvie INC. | $33.73 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $27.50 | 2019-2020 | |
| Phadia US INC. | $13.88 | 2019 | |
| Sanofi Pasteur INC. | $12.63 | 2019 | |
| Novo Nordisk INC | $12.50 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Chomsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.